Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Why It Matters

Ark’s fresh bets highlight a strategic shift toward value‑oriented growth plays, potentially reshaping capital flows into emerging tech sectors. Investors watch these allocations as a barometer for broader market sentiment on innovation stocks.

Key Takeaways

• Ark added Figma, now 0.66% of ARKK.
• CRISPR now second-largest holding, 6.64% weight.
• CoreWeave gains AI GPU exposure, 2% portfolio share.
• Figma's sales rose 40% YoY, margins 14%.
• CoreWeave targets hardware‑constrained market with Nvidia GPUs.

Pulse Analysis

Ark Invest’s latest rebalancing underscores a nuanced approach to innovation investing. After a stretch of volatile returns, the firm appears to be hunting for "bargain" opportunities that still fit its high‑growth thesis. By increasing exposure to Figma, CRISPR Therapeutics, and CoreWeave, Ark is diversifying across software design, biotech breakthroughs, and AI infrastructure—three pillars that could drive the next wave of digital transformation. This tactical shift reflects a broader industry trend where investors seek upside potential at more reasonable valuations.

Figma’s addition comes on the back of a 40% year‑over‑year sales surge and a solid 14% operating margin, suggesting the design‑collaboration platform is gaining traction despite recent price volatility. CRISPR Therapeutics, already a marquee holding, now commands over 6% of ARKK, positioning Ark to benefit from any successful commercialization of its gene‑editing pipelines. Meanwhile, CoreWeave’s 2% weighting leverages its partnership with Nvidia’s Rubin GPUs, giving the fund exposure to the escalating demand for AI‑accelerated compute in a market constrained by hardware supply.

For investors, Ark’s moves provide a lens into where capital is likely to flow in the coming months. The selections balance near‑term revenue growth with long‑term, potentially disruptive breakthroughs, but they also carry sector‑specific risks—software competition, regulatory hurdles in biotech, and the cyclical nature of AI hardware demand. Monitoring earnings, pipeline milestones, and macro‑level AI spending will be crucial for assessing whether these "bargain" picks deliver the outsized returns Ark’s track record promises.